Acacia Research, a California company frequently described as a “patent troll,” says that it has acquired 13 patents for inhaler technology from “a major medical company.” Company CEO Paul Ryan said, “Acacia continues to increase the number of patent portfolios we control in the medical technology sector.” The type of inhaler covered by the patents was not specified.
According to the company, it controls more than 200 patent portfolios in a wide variety of industries; the new acquisition appears to be their first drug delivery technology. Acacia prides itself on its ability “to bring and sustain legal actions against infringers,” which it does regularly.
Read the Acacia press release.
